Biosenic (FRA:BT1) Total Current Liabilities

: €12.16 Mil (As of Jun. 2023)

View and export this data going back to 2015. Start your Free Trial

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Biosenic's total current liabilities for the quarter that ended in Jun. 2023 was €12.16

Biosenic Total Current Liabilities Historical Data

The historical data trend for Biosenic's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosenic Annual Data

Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22

Total Current Liabilities

9.34 9.34 9.79 1.49 10.35

Biosenic Semi-Annual Data

Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23

Total Current Liabilities 5.47 1.49 6.69 10.35 12.16

Biosenic Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Biosenic's Total Current Liabilities for the fiscal year that ended in Dec. 2022 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 2.236 + 5.058

+ Other Current Liabilities + Current Deferred Liabilities

= 3.059 + 0

= 10.35

Biosenic's Total Current Liabilities for the quarter that ended in Jun. 2023 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 2.728 + 9.339

+ Other Current Liabilities + Current Deferred Liabilities

= 0.089 + 0

= 12.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Biosenic Total Current Liabilities Related Terms
Thank you for viewing the detailed overview of Biosenic's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Biosenic (FRA:BT1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biosenic (FRA:BT1) » Definitions » Total Current Liabilities

Comparable Companies

XBRU:OXUR XBRU:CYAD XBRU:ALIMG OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX BGNE SZSE:300122 ALNY OCSE:GMAB XKRX:068270 BMRN XBRU:UCB

Traded in Other Exchanges

BIOS:Belgium

Address

Rue Granbonpre 11, Batiment H (bte 24), Mont-St-Guibert, Gosselies, BEL, 1435

Website

https://www.biosenic.com

Biosenic is engaged in the development of cell therapy products for orthopaedics and bone diseases. The product pipeline of the company includes; ALLOB for treatment of delayed-union fractures, spinal fusion procedures and revision spinal fusion, and PREOB. In addition, the firm is also focused on conducting preclinical research on next-generation product candidates such as combined cell-matrix products for large bone defects and maxillofacial applications.

Biosenic (FRA:BT1) Headlines

No Headlines

Biosenic Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Total Current Liabilities																5.47	1.49	6.69	10.35	12.16

Total Current Liabilities	=	Accounts Payable & Accrued Expense	+	Short-Term Debt & Capital Lease Obligation
	=	2.236	+	5.058
	+	Other Current Liabilities	+	Current Deferred Liabilities
	=	3.059	+	0
	=	10.35